Skandinaviska Enskilda Banken Ab (Publ) Janux Therapeutics, Inc. Transaction History
Skandinaviska Enskilda Banken Ab (Publ)
- $21.6 Billion
- Q4 2024
A detailed history of Skandinaviska Enskilda Banken Ab (Publ) transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Skandinaviska Enskilda Banken Ab (Publ) holds 205,167 shares of JANX stock, worth $6.16 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
205,167
Previous 34,647
492.16%
Holding current value
$6.16 Million
Previous $1.57 Million
597.84%
% of portfolio
0.05%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding JANX
# of Institutions
228Shares Held
54.7MCall Options Held
687KPut Options Held
357K-
Ra Capital Management, L.P. Boston, MA10.4MShares$311 Million8.99% of portfolio
-
Janus Henderson Group PLC London, X03.56MShares$107 Million0.1% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.52MShares$106 Million7.18% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.06MShares$91.9 Million0.3% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$70.3 Million0.0% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $1.25B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...